黑色素瘤免疫治疗现状及研究进展

方翠华; 潘茂华; 周隆参; 覃宇城; 黄亚铭; 马佳; 陈熙; 杨照青

doi:10.12259/j.issn.2095-610X.S20230519

黑色素瘤免疫治疗现状及研究进展

doi: 10.12259/j.issn.2095-610X.S20230519

1.
云南经济管理学院医学院，云南昆明　650106
2.
广西上林县人民医院内科，广西上林　530500
3.
昆明医科大学基础医学院，云南昆明　650500

基金项目: 国家自然科学基金资助项目（U1802286，31860604）

详细信息

作者简介:
方翠华（1981～），女，云南宜良人，在读硕士研究生，副教授，主要从事病原生物学研究工作

通讯作者:
陈熙，E-mail：17431524@qq.com

杨照青，E-mail：zhaoqingy92@hotmail.com

中图分类号: R739.5
计量
- 文章访问数: 3331
- HTML全文浏览量: 3541
- PDF下载量: 111
- 被引次数: 0
出版历程
- 收稿日期: 2023-01-24
- 网络出版日期: 2023-05-11
- 刊出日期: 2023-05-25

Current Status and Research Progress of Immunotherapy for Melanoma

1.
Medical College of Yunnan University of Economics and Management，Kunming Yunnan 650106
2.
Dept. of Internal Medicine，Shanglin County People’s Hospital，Shanglin Guangxi 530500
3.
Basic College of Kunming Medical University， Kunming Yunnan 650500，China

摘要

摘要: 黑色素瘤是一种致命性的恶性肿瘤疾病，尽管多年的临床研究证明其治疗有多种方式，如手术治疗、化疗、放疗、靶向治疗等，但由于敏感度低、毒副作用强、耐药性强、疗效都不佳，鉴于目前免疫疗法在肿瘤疾病治疗中的广泛应用，现对近年黑色素瘤的免疫治疗的进展进行综述。
- 黑色素瘤 /
- 免疫疗法 /
- 细胞因子 /
- 肿瘤疫苗 /
- 疟原虫
Abstract: Melanoma is a highly lethal skin malignant tumor. Although years of clinical studies have proved that there are various methods for its treatment, such as surgery, chemotherapy, radiotherap, targeted therapy, etc., due to its low sensitivity, strong toxic and side effects, and poor efficacy, in view of the wide application of immunotherapy in the treatment of tumor diseases, the author reviewed the progress of immunotherapy of melanoma in recent years.
- Melanoma /
- Immunotherapy /
- Cytokines /
- Tumor vaccines /
- Plasmodium

HTML全文

参考文献(29)

[1]	Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians,2018,68(6):394-424. doi: 10.3322/caac.21492
[2]	Carrs S,Smith C,Wermberg J. Epidemiology and risk factors melanoma[J]. Surg Clin North Am,2020,100(1):1-12. doi: 10.1016/j.suc.2019.09.005
[3]	Patel H,Yacooub N,Mishra R,et al. Current advances in the treatment of BRAF-mutant melanoma[J]. Cancers Basel,2020,12(2):482-491.
[4]	Zhu Z,Liu W,Gotileb V. The rapidly evolving therapies for advanced melanoma-towards immunotherapy,molecular targeted therapy,and beyond[J]. Crit Rev Oncol Hematol,2016,99(1):91-99.
[5]	Davis L E,Shalin S C,Tackett A J. Current state of melanoma diagnosis and treatment[J]. Cancer Biol Ther,2019,20(11):1366-1379. doi: 10.1080/15384047.2019.1640032
[6]	Lugobic-mihic L,Ćesic D,Vukovic P,et al. Melanoma development:Current knowledge on melanoma pathogenesis[J]. Acta Dermatovenerol Croat,2019,27(3):163-168.
[7]	Babcan A. Eroglu Z,Treatment options for advanced melanoma after anti-PD-1 therapy[J]. Current Oncology Reports,2020,22(4):38-42. doi: 10.1007/s11912-020-0894-z
[8]	Haanen J,Ernstoffff M S,Wangf Y,et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy:Review of the literature and personalized risk-based prevention strategy[J]. Annals of Oncology,2020,31(6):724-744. doi: 10.1016/j.annonc.2020.03.285
[9]	Hmaidm O,Ismil V,Puzanov I. Intratumoral immunotherapy-update 2019[J]. The Oncologist,2020,25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438
[10]	Kremenovic M,Schenk M,Leed J. Clinical and molecular insights into BCG immunotherapy for melanoma[J]. Journal of Internal Medicine,2020,6(288):1-16.
[11]	Twitty C G,Huppert L A,Daud A I. Prognostic biomarkers for melanoma immunotherapy[J]. Current Oncology Reports,2020,22(3):25-32. doi: 10.1007/s11912-020-0886-z
[12]	Ellithi M,Elnair R,Chang G V,et al. Toxicities of immune checkpoint inhibitors: It is-ending adverse reactions and more[J]. Cureus,2020,12(2):e6935-e6943.
[13]	郭军,崔传亮. 皮肤黑色素瘤瘤体内治疗进展[J]. 肿瘤医学论坛,2016,21(6):556-559.
[14]	Mcomasters K M,Egger M E,Edwards M J,et al. Final results of the sunbelt melanoma trial: A multi-institutional prospective randomized phase iii study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy[J]. J Clin Oncol,2016,37(1):S35-45.
[15]	Zarstsky J M,Garciadiaz A,Shin D S,et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma[J]. N Engl J Med,2016,375(9):819-829. doi: 10.1056/NEJMoa1604958
[16]	Eggermint A M M,Blank C U,Mandala M,et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizu mab in high-risk stage Ⅲ melanoma:Updated results from the EORTC 1325-MG/KEYNOTE-054 trial[J]. J Clin Oncol,2020,38(33):3925-3936. doi: 10.1200/JCO.20.02110
[17]	Ascierto P A,Vecchiom D,Mandala M,et al. Adjuvant nivolumab versus ipilimumab in resected stage ⅢB-C and stage Ⅳ melanoma (CheckMate 238): 4-year results from a multicentre,double-blind,randomised,controlled,phase 3 trial[J]. Lancet Oncol,2020,21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0
[18]	Yokota K,Uchi H,Uhara H,et al. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage Ⅲ/Ⅳ melanoma:Japanese subgroup analysis from the phase 3 checkmate 238 study[J]. J Dermatol,2019,46(12):1197-1201. doi: 10.1111/1346-8138.15103
[19]	Lohmueller J,Finn O J. Current modalities in cancer immunotherapy: Immunomodulatory antibodies,CARs and vaccines[J]. Pharmacol Ther,2017,3(178):31-47.
[20]	Ott P A,Hu Z,Keskin D B,et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature,2017,547(7662):217-221. doi: 10.1038/nature22991
[21]	Williegen W W,Bloemendal M,Gerritsen W R,et al. Dendritic cell cancer therapy: Vaccinating the right patient at the right time[J]. Frontiers in Immunology,2018,9(15):22-65. doi: 10.3389/fimmu.2018.00022
[22]	Javed A, Sato S, Sato T, Autologous melanoma cell vaccine using monocyte-derived dendritic cells （NBS20/eltrapuldencel-T）[J]. Future Oncology, 2016, 12（6）: 751–762.
[23]	Merhavi-shohame E,Ihzhaki O,Markel G,et al. Adoptive cell therapy for metastatic melanoma[J]. Cancer J,2017,23(1):48-53. doi: 10.1097/PPO.0000000000000240
[24]	Andersen R,Donia M,Ellebaek E,et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen[J]. Clin Cancer Res,2016,22(15):3734-3745. doi: 10.1158/1078-0432.CCR-15-1879
[25]	Qian X Y,Pan Y L. Current status of immunotherapy for malignant melanoma[J]. Zhejiang Medical Journal,2016,3(10):8-18.
[26]	Chen X P,Qin L,Hu W,et al. The mechanisms of action of plasmodium infection against cancer[J]. Cell Commun Signal,2021,19(74):8-9.
[27]	Yang Y,Liu Q,Lu J,et al. Exosomes from plasmodium-infected hosts inhibit tumor angiogenesis in a murine lewis lung cancer model[J]. Oncogenesis,2017,6(6):e351-e359. doi: 10.1038/oncsis.2017.52
[28]	Wang B F,Li Q Y,Chen X P,et al. Plasmodium infection inhibits tumor angiogenesis through effects on tumor-associated macrophages in a murine implanted hepatoma model[J]. Cell Communication and Signaling,2020,18(157):17-32.
[29]	Bibbo S,Ianiro G,Giambo F,et al. Role of gut microbiome on immunotherapy efficacy in melanoma[J]. Hum Vaccines Immunother,2021,5(17):1-6.

相关文章(20)

[1]	钱石兵, 史会萍, 李艳秋, 杨镕羽, 段开文. 根尖牙乳头干细胞成骨分化的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240926
[2]	李芬, 赵婕, 张海溪, 张琳, 辜学忠. 噬血细胞综合征患者的铁代谢指标、细胞因子和肝功能的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241115
[3]	董建芳, 尹茜晶, ）陈祖聪, 张雪飞, 周泽平. 免疫相关分子在原发免疫性血小板减少症中的研究进展, 昆明医科大学学报.
[4]	吴希兰, 沈红, 石素胜, 张智慧, 郭蕾, 王芳. PD-L1、BRAF^V600E、CD68蛋白表达及肿瘤浸润淋巴细胞在恶性黑色素瘤诊断中的意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220923
[5]	赵琨, 肖云, 杨纯, 严志凌, 董敏娜, 向柄全, 肖茗耀. 白细胞介素-4在脂多糖诱导急性肺损伤模型中的保护作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220805
[6]	张海霞, 李磊, 金磊, 叶沛婧, 孙传政. 云南省肿瘤医院1 203例黑色素瘤临床分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220808
[7]	刘幸, 李海雯, 黄红丽, 沈凌筠, 张乐, 刘向芳, 张文林, 王璐. 益生菌强化肠内营养支持对重症急性胰腺炎患者胃肠道功能和炎症因子的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211116
[8]	杨金荣, 武坤, 聂波, 贺振新, 杨雨宇, 孙杰, 曾云. 成人HPS临床特征及多种细胞因子水平与预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211220
[9]	周玮莎, 张乐, 彭静, 陈寿坤, 刘梦君, 符晓, 唐志飞, 岳云璇. 血浆置换加双重血浆分子吸附对自身免疫性肝炎合并肝衰竭的细胞因子的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210414
[10]	赵维佳, 李红宾, 陈宗翰. 窄谱中波紫外线联合卡泊三醇治疗银屑病症状转归及患者治疗前后外周血细胞因子水平评价, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201227
[11]	范旭, 冯煜然, 朱梅. 微波消融联合免疫疗法治疗肿瘤的研究进展, 昆明医科大学学报.
[12]	秋玉珍. 多发性骨髓瘤的免疫基因治疗, 昆明医科大学学报.
[13]	张洋. 炎症及氧化应激反应在慢性阻塞性肺疾病发病机制中的研究进展, 昆明医科大学学报.
[14]	薛恩忠. 高血压合并糖尿病患者血清粘附因子与炎性因子水平及相关性研究, 昆明医科大学学报.
[15]	杨婧. Th17细胞及相关细胞因子在原发性胆汁性肝硬化患者的表达, 昆明医科大学学报.
[16]	杨德兴. 脓毒性休克对恒河猴血流动力学、器官损伤及细胞因子释放的影响, 昆明医科大学学报.
[17]	张振光. 椎管内恶性黑色素细胞瘤1例报道, 昆明医科大学学报.
[18]	李玉晓. 大蒜新素对变应性鼻炎患者外周血白介素4和γ干扰素的影响, 昆明医科大学学报.
[19]	周义忠. 血IL-10、IL-5、IL-2、IFN-γ水平在反复腹痛患儿及其家庭成员中的比较, 昆明医科大学学报.
[20]	伍尚敏. Shh在血管瘤中的表达及意义, 昆明医科大学学报.